Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00102765 · ClinicalTrials.gov registry record · Phase 4

Study Of Asthma In Patients Of African Descent

A Phase 4 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 4
Development phase
479
Enrollment target

NCT00102765: Completed Phase 4 study, sponsored by GlaxoSmithKline.

NCT00102765 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 479 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00102765, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 4
Development phase
479 participants
Enrollment target

Study Summary

This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests. The purpose of this study is to see if one asthma drug (fluticasone propionate/salmeterol) is better in reducing the number of asthma exacerbations compared with another drug (fluticasone propionate alone)

Interventions

  • DRUG fluticasone propionate/salmeterol powder
  • DRUG fluticasone propionate powder

Trial Details

FieldValue
Enrollment Target 479 participants
Start Date 2004-11
Est. Completion 2007-04
Phase Phase 4
GlaxoSmithKline

1,345 total trials

What the finished NCT00102765 record still lists

NCT00102765 is an interventional study that assigns participants to a tested intervention. The registered 479 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which fluticasone propionate/salmeterol powder is the first listed.

NCT00102765 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00102765 about?

NCT00102765 is a clinical study titled "Study Of Asthma In Patients Of African Descent". This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests. The purpose of this study is to see if one asthma drug (fluticasone propionate/salmeterol) is better in reducing the...

What is the current status of trial NCT00102765?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 479 participants. The study started on 2004-11. Estimated completion is 2007-04.

What interventions are being tested in trial NCT00102765?

The interventions under investigation include: fluticasone propionate/salmeterol powder (DRUG), fluticasone propionate powder (DRUG).

Who is sponsoring clinical trial NCT00102765?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00102765's enrollment target sits among peer trials

479 182nd of 2000 higher than 1,819 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04221542 · 479 participants · Phase 1

    Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  • NCT01954992 · 480 participants · Phase 3

    Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

  • NCT03023696 · 480 participants · NA

    Can Prophylactic Foraminotomy Prevent C5 Palsy

  • NCT04948060 · 480 participants · NA

    Tribally Engaged Approaches to Lung Screening (TEALS)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00102765, the US trial registry maintained by the National Library of Medicine. NCT00102765 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.